Log In
BCIQ
Print this Print this
 

Bortezomib BXCL101

  Manage Alerts
Collapse Summary General Information
Company BioXcel Corp.
DescriptionReversible inhibitor of the chymotrypsin-like activity of the 26S proteasome
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationNeurofibromatosis
Indication DetailsTreat existing lesions and prevent the formation of new lesions related to Neurofibromatosis Type 2 (NF2); Treat Neurofibromatosis Type 2 (NF2)
Regulatory Designation U.S. - Orphan Drug (Treat existing lesions and prevent the formation of new lesions related to Neurofibromatosis Type 2 (NF2))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today